Skip to content

Author

V. Aboyans

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Nov 2026

PCSK9-Targeting Therapies and Mortality: A Systematic Review and Meta-Analysis of Randomized Trials.

PCSK9-targeting therapies were associated with lower all-cause mortality and fewer ischemic events across trial populations, and the predominant contribution of large cardiovascular outcome trials enrolling populations with known atherosclerosis and using PCSK9 antibodies limits the ability to infer a survival benefit.

E. Navarese, E. Ruscio, Hai-Xiang Zheng et al. · 0 citations
Open access Oct 2026

Low-grade inflammation and cardiovascular events among patients with chronic kidney disease.

In CKD patients not yet on kidney replacement therapy, systemic low-grade inflammation, measured through hs-CRP, is associated with occurrence of cardiovascular events independently of traditional risk factors, including a history of ASCVD.

J. Motiejūnaitė, Leila Benamara, Emilie Moutard et al. · 0 citations
Open access Oct 2026

Determinants and associations of health-related quality of life with mortality in acute and chronic heart failure: findings from the ESC HF III Registry.

AIMS To assess the demographic, clinical, behavioural, and treatment factors associated with health-related quality of life (HRQoL) in heart failure (HF), examine the association between HRQoL and mortality, and evaluate changes in HRQoL over 1-year. METHODS We analysed the ESC EORP Heart Failure III Registry, includ...

M. Walli-Attaei, L. Lund, R. Luengo-Fernandez et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.